Company intelligence / Profile preview

Ji Ming Biopharmaceutical

Suzhou, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

Jiming Biopharmaceutical is a clinical-stage biotechnology company based in Suzhou, China, specializing in the discovery and development of innovative small molecule therapeutics. The company focuses on high-value targets in oncology and metabolic diseases, utilizing a structure-based drug design platform to create highly selective inhibitors. Its lead programs include JM-001, a potent KRAS G12D inhibitor, and other candidates targeting various KRAS mutations and FGFR4. Jiming Biopharmaceutical aims to address significant unmet medical needs in difficult-to-treat cancers such as pancreatic and colorectal malignancies.

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Beyond the preview

Go deeper on Ji Ming Biopharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ji Ming Biopharmaceutical.

Explore the full profile